Higher doses of upadicitinib show added benefits for adults with moderate-to-severe atopic dermatitis (AD) when compared to dupilumab, according to a new study.
top of page
it's where dermatology lives
bottom of page
Higher doses of upadicitinib show added benefits for adults with moderate-to-severe atopic dermatitis (AD) when compared to dupilumab, according to a new study.
Comments